Hexaminolevulinate
drugOn this page
Also known as HexvixHexaminolevulinate (hydrochloride)
Summary
Hexaminolevulinate (CHEMBL1201784) is an approved small molecule (ATC V04CX06); indicated across 3 conditions including lichen planus and dysplasia of cervix.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V04CX06
- Indications: 3 conditions
- Clinical trials: 13
- Chemistry: 215.29 Da · C11H21NO3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201784 |
| Name | Hexaminolevulinate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 6433083 |
| ATC | V04CX06 |
| Molecular formula | C11H21NO3 |
| Molecular weight | 215.29 |
| InChIKey | RYQOILLJDKPETL-UHFFFAOYSA-N |
SMILES: CCCCCCOC(=O)CCC(=O)CN
IUPAC name: hexyl 5-amino-4-oxopentanoate
Also known as: Hexaminolevulinate, Hexvix, HEXAMINOLEVULINATE, hexaminolevulinate, Hexaminolevulinate (hydrochloride)
Parent form; salt/anhydrous children: CHEMBL1201785
Patent coverage: 406 distinct patent families (1,233 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 5-hydroxytryptamine receptor 2C, Prostaglandin G/H synthase 1.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| Q63921 | 5.03 | AC50 | 9400 | nM | CHEMBL_ACT_25174806 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| lichen planus | 2 | MONDO:0006572 | EFO:1000726 |
| dysplasia of cervix | 2 | MONDO:0006736 | EFO:1000910 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| Not specified | 3 |
| PHASE4 | 2 |
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06548438 | PHASE4 | NOT_YET_RECRUITING | The Impact of PDD During TURB for NMIBC |
| NCT00785694 | PHASE4 | WITHDRAWN | Recurrence of Bladder Cancer After Transurethral Resection With Hexvix |
| NCT00052637 | PHASE3 | COMPLETED | Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer |
| NCT00233402 | PHASE3 | COMPLETED | Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy |
| NCT00412971 | PHASE3 | COMPLETED | A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer |
| NCT01282515 | PHASE2/PHASE3 | COMPLETED | Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT |
| NCT00285701 | PHASE1/PHASE2 | COMPLETED | Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study |
| NCT00708942 | PHASE2 | TERMINATED | Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 |
| NCT01551407 | PHASE2 | TERMINATED | Detection of Bladder Tumors After 30 Min Instillation of Hexvix |
| NCT01050309 | PHASE1 | COMPLETED | An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers |
| NCT02660645 | Not specified | RECRUITING | Blue Light Cystoscopy With Cysview® Registry |
| NCT00634621 | Not specified | COMPLETED | Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer |
| NCT02012036 | Not specified | COMPLETED | Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.